NCT01748578View on ClinicalTrials.gov

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

March 31, 2013

Conditions
Dry Eye
Interventions
DRUG

EBI-005-1

EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo

DRUG

EBI-005-1 Placebo

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Eleven Biotherapeutics

INDUSTRY